FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981707459> ?p ?o ?g. }

• W2981707459 endingPage "5541" @default.
• W2981707459 startingPage "5541" @default.
• W2981707459 abstract "Abstract For patients with acute myeloid leukemia (AML) who fail to achieve complete remission (CR) after induction chemotherapy, allogeneic stem cell transplantation (Allo-SCT) can provide leukemia control and result in long-term survival (Blood. 2016;127(1):53-61; BBMT. 2003;9(12):766-71; BBMT. 2016;22(10):1867-73). In this retrospective study, we analyzed the outcomes of patients at our institution who had chemotherapy-resistant AML and subsequently received Allo-SCT. We defined “chemotherapy-resistant AML” as not achieving CR prior to transplant according to the Center for International Blood & Marrow Transplant Research (CIBMTR) reporting criteria after one or more cycles of induction chemotherapy. We queried our CIBMTR reporting data and identified 44 patients age ≥ 18 years with AML who were not in CR and who were transplanted from 2009 to 2015. Patient records were reviewed and the following variables were collected: age, KPS, cytogenetic risk, number of prior chemotherapy cycles, chemotherapy regimens, transplant conditioning regimens, stem cell donor characteristics, blasts percentage at time of transplantation, and key transplant outcomes (overall survival, OS; relapse mortality; and, non-relapse mortality, NRM). Key transplant outcomes were segregated by blast percentage at time of transplantation (≤5% v. >5%) and analyzed. The median age was 60 years (range 20-73 years), and the median KPS was 62%(range 50-100%). Most patients received 2 or more induction regimens prior to transplant (n=32, 72%). Based on the MRC 2010 cytogenetic risk classification system (Blood. 2010 116:354-365), cytogenetic risk was classified as intermediate risk in 23 patients and unfavorable risk in 21 patients. Molecular markers and targeted gene sequencing were not available in most cases. Myeloablative conditioning was used in 29 patients (65%). Stem cell donors were as follows: matched related donor (n= 6; 13.9%), 10/10 or 9/10 matched unrelated donor (n=25, 56%), haploidentical donor (n= 6; 13.9%), and cord blood donor (n= 6; 13.9%). Stem cell sources were as follows: peripheral blood (n= 34; 79%), bone marrow (n= 3, 6.9%), and cord blood (n= 6; 13.9%). Blast count at the time of transplant ranged from 5% at the time of transplant. With a median follow up of 553days, cumulative 1-year and 2-year survival for the entire cohort was 49.5% and 37.8%, respectively. Most of the deaths occurred within the first year after the transplant (n=21; 49%). Of the 30 deaths, relapse preceded death in 17 patients (57%). A graphical representation of outcomes (swimmer plot) summarizes the post-transplant outcome for each of the 44 patients (Figure 1). Our data suggest that elevated blast percentage pre-transplant may impact survival outcomes in patients with chemotherapy-resistant AML, through the results were not statistically significant (Figure 1; ≤5% blasts median OS 638 days v. >5% 228 days; p=0.14). Approximately equal numbers of patients died from disease relapse and NRM in this high-risk cohort regardless of the blast percentage prior to transplantation (Figure 1). A third of patients are currently alive and disease free (n=14; 32%), with relatively equal numbers in the ≤5% blast and >5% blast groups (n=8 v. n=6). Although our study involves a small population of patients, we conclude that the approach to this high-risk subgroup of patients requires further study and a more standardized approach. Strategies to reduce non-relapse mortality (improved conditioning regimens) and relapse mortality (post-transplant maintenance strategies) are equally important in this group who otherwise have few treatment options. Download : Download high-res image (113KB) Download : Download full-size image Figure 1 . Disclosures Lin: Jazz Pharmaceuticals: Consultancy. Ganguly: Amgen: Other: Advisory Board; Seattle Genetics: Speakers Bureau. Skikne: Celgene Corporation: Employment, Equity Ownership." @default.
• W2981707459 created "2019-11-01" @default.
• W2981707459 creator A5008376636 @default.
• W2981707459 creator A5035236340 @default.
• W2981707459 creator A5036228481 @default.
• W2981707459 creator A5039680248 @default.
• W2981707459 creator A5040104069 @default.
• W2981707459 creator A5046911143 @default.
• W2981707459 creator A5050970683 @default.
• W2981707459 creator A5052064208 @default.
• W2981707459 creator A5079800586 @default.
• W2981707459 creator A5086587597 @default.
• W2981707459 date "2017-12-07" @default.
• W2981707459 modified "2023-09-28" @default.
• W2981707459 title "Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis" @default.
• W2981707459 doi "https://doi.org/10.1182/blood.v130.suppl_1.5541.5541" @default.
• W2981707459 hasPublicationYear "2017" @default.
• W2981707459 type Work @default.
• W2981707459 sameAs 2981707459 @default.
• W2981707459 citedByCount "0" @default.
• W2981707459 crossrefType "journal-article" @default.
• W2981707459 hasAuthorship W2981707459A5008376636 @default.
• W2981707459 hasAuthorship W2981707459A5035236340 @default.
• W2981707459 hasAuthorship W2981707459A5036228481 @default.
• W2981707459 hasAuthorship W2981707459A5039680248 @default.
• W2981707459 hasAuthorship W2981707459A5040104069 @default.
• W2981707459 hasAuthorship W2981707459A5046911143 @default.
• W2981707459 hasAuthorship W2981707459A5050970683 @default.
• W2981707459 hasAuthorship W2981707459A5052064208 @default.
• W2981707459 hasAuthorship W2981707459A5079800586 @default.
• W2981707459 hasAuthorship W2981707459A5086587597 @default.
• W2981707459 hasConcept C126322002 @default.
• W2981707459 hasConcept C141071460 @default.
• W2981707459 hasConcept C143998085 @default.
• W2981707459 hasConcept C2776611710 @default.
• W2981707459 hasConcept C2776694085 @default.
• W2981707459 hasConcept C2778336483 @default.
• W2981707459 hasConcept C2778461978 @default.
• W2981707459 hasConcept C2778729363 @default.
• W2981707459 hasConcept C2780073493 @default.
• W2981707459 hasConcept C2911091166 @default.
• W2981707459 hasConcept C71924100 @default.
• W2981707459 hasConceptScore W2981707459C126322002 @default.
• W2981707459 hasConceptScore W2981707459C141071460 @default.
• W2981707459 hasConceptScore W2981707459C143998085 @default.
• W2981707459 hasConceptScore W2981707459C2776611710 @default.
• W2981707459 hasConceptScore W2981707459C2776694085 @default.
• W2981707459 hasConceptScore W2981707459C2778336483 @default.
• W2981707459 hasConceptScore W2981707459C2778461978 @default.
• W2981707459 hasConceptScore W2981707459C2778729363 @default.
• W2981707459 hasConceptScore W2981707459C2780073493 @default.
• W2981707459 hasConceptScore W2981707459C2911091166 @default.
• W2981707459 hasConceptScore W2981707459C71924100 @default.
• W2981707459 hasLocation W29817074591 @default.
• W2981707459 hasOpenAccess W2981707459 @default.
• W2981707459 hasPrimaryLocation W29817074591 @default.
• W2981707459 hasRelatedWork W2057726523 @default.
• W2981707459 hasRelatedWork W2524516186 @default.
• W2981707459 hasRelatedWork W2531365967 @default.
• W2981707459 hasRelatedWork W2548788131 @default.
• W2981707459 hasRelatedWork W2561661028 @default.
• W2981707459 hasRelatedWork W2572075405 @default.
• W2981707459 hasRelatedWork W2574061198 @default.
• W2981707459 hasRelatedWork W2584938620 @default.
• W2981707459 hasRelatedWork W2589000699 @default.
• W2981707459 hasRelatedWork W2589212875 @default.
• W2981707459 hasRelatedWork W2589740392 @default.
• W2981707459 hasRelatedWork W2594825495 @default.
• W2981707459 hasRelatedWork W2595782604 @default.
• W2981707459 hasRelatedWork W2966140930 @default.
• W2981707459 hasRelatedWork W2979910189 @default.
• W2981707459 hasRelatedWork W2980628189 @default.
• W2981707459 hasRelatedWork W3002218311 @default.
• W2981707459 hasRelatedWork W3141276451 @default.
• W2981707459 hasRelatedWork W3174865378 @default.
• W2981707459 hasRelatedWork W567063424 @default.
• W2981707459 hasVolume "130" @default.
• W2981707459 isParatext "false" @default.
• W2981707459 isRetracted "false" @default.
• W2981707459 magId "2981707459" @default.
• W2981707459 workType "article" @default.